DVAX vs. ACAD, ALKS, BOLT, CORT, GILD, LGND, MRK, FOLD, MNKD, and CLDX
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include ACADIA Pharmaceuticals (ACAD), Alkermes (ALKS), Bolt Biotherapeutics (BOLT), Corcept Therapeutics (CORT), Gilead Sciences (GILD), Ligand Pharmaceuticals (LGND), Merck & Co., Inc. (MRK), Amicus Therapeutics (FOLD), MannKind (MNKD), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector.
Dynavax Technologies vs. Its Competitors
Dynavax Technologies (NASDAQ:DVAX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.
Dynavax Technologies has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Dynavax Technologies currently has a consensus price target of $24.33, suggesting a potential upside of 147.54%. ACADIA Pharmaceuticals has a consensus price target of $29.12, suggesting a potential upside of 43.01%. Given Dynavax Technologies' higher probable upside, research analysts clearly believe Dynavax Technologies is more favorable than ACADIA Pharmaceuticals.
In the previous week, ACADIA Pharmaceuticals had 11 more articles in the media than Dynavax Technologies. MarketBeat recorded 14 mentions for ACADIA Pharmaceuticals and 3 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.83 beat ACADIA Pharmaceuticals' score of 0.23 indicating that Dynavax Technologies is being referred to more favorably in the media.
ACADIA Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals has a net margin of 21.80% compared to Dynavax Technologies' net margin of -16.67%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Dynavax Technologies' return on equity.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
ACADIA Pharmaceuticals beats Dynavax Technologies on 12 of the 17 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 10/15/2025 by MarketBeat.com Staff
